Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cellular Biomedicine Group Inc (NASDAQ:CBMG)

14.07
Delayed Data
As of Aug 26
 -0.29 / -2.02%
Today’s Change
10.44
Today|||52-Week Range
25.20
-34.53%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$198.4M

Company Description

Cellular Biomedicine Group, Inc. is a biomedicine company. It engages in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The company's developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. It operates in two segments: Biomedicine and Consulting. The Biomedicine segment is in development stage, conducting research and development activities to commercialize stem cell and immune cell therapeutics, related tools and products. The Consulting segment provides services to foreign and domestic companies seeking access to the U.S. capital markets. Cellular Biomedicine Group was founded in 2009 and is headquartered in Palo Alto, CA.

Contact Information

Cellular Biomedicine Group, Inc.
19925 Stevens Creek Boulevard
Cupertino California 94301
P:(408) 973-7884
Investor Relations:

Employees

Shareholders

Mutual fund holders4.67%
Other institutional4.14%
Individual stakeholders29.04%

Top Executives

Bizuo LiuCEO, CFO, Secretary & Director
Richard L. WangChief Operating Officer
Maxwell WangDirector-Medical Research
Yihong YaoChief Scientific Officer
Li ZhangVice President-Technology & Manufacturing